Observational Study of Adult Patients Receiving Dupixent for Atopic Dermatitis (AD)

  • STATUS
    Recruiting
  • End date
    Apr 12, 2026
  • participants needed
    1000
  • sponsor
    Sanofi
Updated on 19 February 2024
atopy
dermatitis
eczema
dupilumab

Summary

Primary Objective:
To characterize the patients who receive Dupixent (dupilumab) for AD in a real-world setting, with respect to their medical history, socio-demographic and disease characteristics, and prior and concomitant treatments of AD
Secondary Objectives:
  • To characterize real-world use patterns of Dupixent for AD (eg, used regimens, reason for initiation of new treatments, concomitant therapies, treatment durations and reasons for discontinuation and/or switching)
  • To assess the long-term effectiveness of Dupixent in adult AD patients in a real-world setting
  • To assess comorbid atopic conditions and effects of treatment in comorbid atopic conditions in adult patients who receive Dupixent for AD
  • To collect safety data on study participants

Description

Participants enrolled in the study will be followed for 5 years.

Details
Condition ATOPIC DERMATITIS, eczema (atopic dermatitis), ATOPIC DERMATITIS, dermatitis, atopic, dermatitis, atopic, eczema (atopic dermatitis)
Age 18years - 100years
Treatment Dupilumab SAR231893 (REGN668)
Clinical Study IdentifierNCT03992417
SponsorSanofi
Last Modified on19 February 2024

Eligibility

Yes No Not Sure

Inclusion Criteria

Initiating treatment with Dupixent for AD according to the country-specific prescribing information. Note: Participants may be eligible if they have already initiated treatment with Dupixent for AD within 6 months before their enrollment in the registry, provided that all core baseline data required (Eczema Area and Severity Index [EASI], Scoring of Atopic Dermatitis [SCORAD], body surface area [of AD involvement] [BSA], Patient-Oriented Eczema Measure [POEM], and Dermatology Life Quality Index [DLQI]) by the registry protocol were captured at the time of initiating Dupixent treatment and are available for entry in the registry database
Able to understand and complete study-related questionnaires
Provide signed informed consent

Exclusion Criteria

Participants who have a contraindication to the drug according to the country-specific prescribing information label
Any condition that, in the opinion of the investigator, may interfere with patient's ability to participate in the study, such as short life expectancy, substance abuse, severe cognitive impairment, or other co-morbidities that can predictably prevent the participant patient from adequately completing the schedule of visits and assessments
Patients currently participating in any interventional clinical trial which modifies patient care
The above information is not intended to contain all considerations relevant
to a patient's potential participation in a clinical trial
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

Study AnnotationsStudy Notes

Notes added here are public and can be viewed by anyone. Notes added here are only available to you and those who you share with.

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.